Trials / Completed
CompletedNCT05894590
Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
Cohort Survey on Non-Acute Safety in Persons With Underlying Diseases Who Are Considered to Be at High Risk of Severe COVID-19 by Using Vaccination Information
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 13,680 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to assess serious adverse events associated with hospitalizations in the non-acute phase after vaccination with the mRNA-1273 vaccine in persons with underlying diseases who are considered to have a high risk of severe exacerbation of COVID-19.
Detailed description
Data collected from the JMDC Claims database from May 2020 to October 2022.
Conditions
Timeline
- Start date
- 2022-11-15
- Primary completion
- 2023-12-20
- Completion
- 2023-12-20
- First posted
- 2023-06-08
- Last updated
- 2024-03-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05894590. Inclusion in this directory is not an endorsement.